Skip to content
Citation only via OpenAlex

Transplantation From Older Donors: Can Senolytics Turn Back the Clock?

Wesley Dixon, Sandy Feng, James Morgan Gardner

Transplantation · 2021 · ▲ 1 citations

Abstract

Senolytics(definition) prevent MITOCHONDRIAL-DNA-induced inflammation and promote the survival of aged organs following transplantation Transplanted organs from older donors have long been associated with worse inflammation, alloreactivity, and posttransplant outcomes,1 but precise mechanisms underlying these phenomena have remained unclear. In the August 2020 issue of Nature Communications, Iske et al2 published a novel study that provides meaningful insights into this problem by linking cell-free mitochondrial DNA (cf-mt-DNA) released by senescent cells with the enhanced immunogenicity of older organs and further demonstrating that diminishing the senescent cell burden in organs from older donor mice—using a class of drugs called senolytics—improved graft survival after transplantation. Age has always been an important factor in evaluating donor organ quality, representing a key component in validated donor risk indices.3,4 While the growing organ shortage demands the use of organs from older donors, in practice, they are often still avoided.5 Mechanisms to meaningfully optimize the quality of such organs—or limit their inflammatory effects—would offer significant value. The emergence of the field of geroscience has drawn attention to the mechanisms underlying aging and age-related disease. Among the many fascinating discoveries to arise from this growing body of research has been an understanding of the role senescent cells play in driving the chronic, sterile, low-grade inflammation that characterizes aging. Senescent cells have been shown to release proinflammatory cytokines and damage-associated molecular patterns, like cf-mt-DNA, that stimulate innate immune responses.6 The authors of the present study found that older C57BL/6 mice (18 mo) have higher levels of circulating cf-mt-DNA than younger mice (2 mo) and that this difference is magnified by ischemia-reperfusion injury. Consistent with prior literature, this study showed that cf-mt-DNA is highly immunogenic and acts, at least partially, through the Toll-like receptor 9 (TLR9) signaling pathway, which is normally associated with the detection of foreign and particularly prokaryotic nucleic acids. In light of its mitochondrial origin, cf-mt-DNA shares many of these same prokaryotic features.7 Treating mice with purified cf-mt-DNA in vivo increased expression of costimulatory molecules and proinflammatory cytokines in splenic dendritic cells in a dose-dependent manner. This stimulatory effect was attenuated by the addition of a TLR9 antagonist. Treating recipients of older mismatched cardiac allografts with this TLR9 antagonist improved allograft survival rates to those observed when transplanting younger organs. Importantly, the authors showed that senescent cells that accumulate with age in the skin, heart, and kidneys are a key source of circulating cf-mt-DNA in older mice. Relating these findings to humans, the authors demonstrated that the plasma of older human organ donors (>55 y) had significantly higher levels of cf-mt-DNA than younger donors (<35 y). Human dendritic cells cocultured with human cf-mt-DNA in vitro upregulated inflammatory maturation and costimulation markers important in mounting alloimmune responses, just as in the murine model. The growing interest in the role of senescent cells in age-related physiology has been accompanied by a parallel focus on a novel class of therapeutics meant to specifically deplete senescent cells, termed senolytics. The first-generation senolytic, a cocktail of dasatinib plus quercetin (DQ), has previously been shown to reduce senescent cell burden in older mice, leading to, for example, improved cardiac ejection fraction in older mice and improved pulmonary function in a murine model of idiopathic pulmonary fibrosis (IPF).8,9 The promising preclinical data supporting the use of senolytics have already prompted clinical trials of DQ in the treatment of IPF.10 In the present study, older C57BL/6 mice treated with DQ for 4 weeks showed reduced levels of senescent cell markers in primary tissues, reduced levels of circulating cf-mt-DNA in serum, and decreased CD4+ and CD8+ T cells expressing interleukin-17A and interferon-γ, respectively, following ischemia-reperfusion injury. The authors then showed that pretreating donor mice with a single dose of DQ before mismatched cardiac transplantation prolonged survival of allografts from older mice, leading to allograft survival rates equivalent to those of young organs. The increase in older allograft survival due to senolytic treatment was particularly pronounced when recipient mice were treated with clinically relevant immunosuppressive regimens. Taken together, the authors suggest that senolytic therapy reduces the senescent cell burden in older donor organs, leading to a diminished release of cf-mt-DNA upon ischemia-reperfusion injury and attenuated dendritic cell activation, which otherwise drives recipient Th1/Th17-mediated alloimmunity. This work has significant potential for a range of applications in transplantation, as understanding (and intervening on) the mechanisms causing augmented immunogenicity of older organs is essential for expanding organ utilization. That said, many questions need to be addressed before these findings might be translated into clinical practice. For example, the precise mechanism of action of senolytics remains undefined, and it is unclear whether the effects are entirely attributable to the clearance of senescent cells.6 Senolytics clearly have other biological effects, including receptor tyrosine kinase inhibition.6,8 Although risk profiles of first-generation senolytics have been shown before in other models, possible adverse consequences and off-target effects in transplanted organs and recipients are largely unknown. Normothermic machine perfusion technologies might provide a valuable platform on which to study these effects. Exploring TLR9 antagonists or methods to specifically deplete cf-mt-DNA may repre

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1097/tp.0000000000003538
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
Dixon, W., Feng, S., &amp; Gardner, J.M. (2021). Transplantation From Older Donors: Can Senolytics Turn Back the Clock?. <em>Transplantation</em>. https://doi.org/10.1097/tp.0000000000003538
Vancouver
Dixon W, Feng S, Gardner JM. Transplantation From Older Donors: Can Senolytics Turn Back the Clock?. Transplantation. 2021. doi:10.1097/tp.0000000000003538.
BibTeX
@article{wesley2021Transp, title = {Transplantation From Older Donors: Can Senolytics Turn Back the Clock?}, author = {Wesley Dixon and Sandy Feng and James Morgan Gardner}, journal = {Transplantation}, year = {2021}, doi = {10.1097/tp.0000000000003538}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings